search
Back to results

CoolSculpting and EMS for the Abdomen (ECA)

Primary Purpose

Body Fat Disorder

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
The ZELTIQ System
Sponsored by
Zeltiq Aesthetics
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional other trial for Body Fat Disorder

Eligibility Criteria

22 Years - 65 Years (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria

  • Male and female subjects > 22 years of age and ≤65 years of age.
  • Subject has not had weight change exceeding 5% of body weight in the preceding month.
  • Subject agrees to maintain her weight (i.e., within 5%) by not making any major changes in diet or exercise routine during the course of the study.
  • Subject agrees to refrain from any new abdominal training exercises during the course of the study.
  • BMI ≤ 30 kg/m2 as determined at screening.
  • Abdominal skin fold thickness 2.0 to 5.0 cm, as measured by caliper below umbilicus.
  • Subject has read and signed a written informed consent form.

Exclusion Criteria

  • Subject has had a surgical procedure(s) in the area of intended treatment.
  • Subject has had an invasive fat reduction procedure (e.g., liposuction, mesotherapy) in the area of intended treatment.
  • Subject has had a non-invasive fat reduction, body contouring and/or skin tightening procedure in the area of intended treatment within the past 12 months.
  • Subject has numbness, tingling or other altered sensation in the treatment area.
  • Subject needs to administer, or has a known history of subcutaneous injections into the area of intended treatment (e.g., heparin, insulin) within the past month.
  • Subject has not had an intrauterine contraceptive device inserted or removed within the past month.
  • Subject has a known history of cryoglobulinemia, cold urticaria, cold agglutinin disease, or paroxysmal cold hemoglobinuria
  • Subject has a known history of Raynaud's disease, or any known condition with a response to cold exposure that limits blood flow to the skin.
  • Subject has a history of bleeding disorder or is taking any medication that in the Investigator's opinion may increase the subject's risk of bruising.
  • Subject has known sensitivity or allergy to isopropyl alcohol and propylene glycol, or latex.
  • Subject is taking or has taken diet pills or supplements within the past month.
  • Subject has any dermatological conditions, such as moderate to excessive skin laxity, or scars in the location of the treatment sites, that may interfere with the treatment or evaluation (stretch marks is not an exclusion).
  • Subject has a metal implant or active implanted device such as a pacemaker, defibrillator, or drug delivery system.
  • Subject has been involved in any type of abdominal muscle training program within the previous 6 months.
  • Subject has pulmonary insufficiency.
  • Subject has a cardiac disorder.
  • Subject has a malignant tumor.
  • Subject has been diagnosed with epilepsy.
  • Subject currently has a fever.
  • Subject is pregnant or intending to become pregnant during the study period (in the next 9 months).
  • Subject is lactating or has been lactating in the past 6 months.
  • Subject is unable or unwilling to comply with the study requirements.
  • Subject is currently enrolled in a clinical study of any other investigational drug or device.
  • Any other condition or laboratory value that would, in the professional opinion of the Investigator, potentially affect the subject's response or the integrity of the data or would pose an unacceptable risk to the subject.

Sites / Locations

  • Marina Plastic Surgery
  • Innovation Research Center
  • Laser & Skin Surgery Center of Northern California
  • Aesthetic Solutions, P.A.

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Fat Reduction

Arm Description

The treatments are designed to see if the fat can be reduced in the abdomen.

Outcomes

Primary Outcome Measures

Safety endpoint in relation to adverse events
Measurement of device- or procedure-related adverse events.
Effectiveness endpoint gauged by photographs
Comparison of pre-treatment- and 12-week post-final treatment photographs to assess visible changes in the abdomen.

Secondary Outcome Measures

3-D imaging
Reduction in abdominal circumference as measured by 3-Dimensional imaging.
Global Aesthetic Improvement Scale (GAIS)
Subject- graded GAIS at 12-week post-final treatment follow-up.

Full Information

First Posted
November 8, 2018
Last Updated
August 14, 2020
Sponsor
Zeltiq Aesthetics
search

1. Study Identification

Unique Protocol Identification Number
NCT03738891
Brief Title
CoolSculpting and EMS for the Abdomen
Acronym
ECA
Official Title
A Feasibility Study to Evaluate Electromagnetic Muscle Stimulation and CoolSculpting for Abdominal Contouring
Study Type
Interventional

2. Study Status

Record Verification Date
August 2020
Overall Recruitment Status
Completed
Study Start Date
November 7, 2018 (Actual)
Primary Completion Date
September 9, 2019 (Actual)
Study Completion Date
September 9, 2019 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Zeltiq Aesthetics

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Evaluate the use of Electromagnetic Muscle Stimulation as an adjunctive treatment to CoolSculpting.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Body Fat Disorder

7. Study Design

Primary Purpose
Other
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
50 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Fat Reduction
Arm Type
Experimental
Arm Description
The treatments are designed to see if the fat can be reduced in the abdomen.
Intervention Type
Device
Intervention Name(s)
The ZELTIQ System
Intervention Description
The CoolSculpting machine will be used to perform the treatments.
Primary Outcome Measure Information:
Title
Safety endpoint in relation to adverse events
Description
Measurement of device- or procedure-related adverse events.
Time Frame
Final post treatment 1 day visit
Title
Effectiveness endpoint gauged by photographs
Description
Comparison of pre-treatment- and 12-week post-final treatment photographs to assess visible changes in the abdomen.
Time Frame
Final post treatment 1 day visit
Secondary Outcome Measure Information:
Title
3-D imaging
Description
Reduction in abdominal circumference as measured by 3-Dimensional imaging.
Time Frame
Final post treatment 1 day visit
Title
Global Aesthetic Improvement Scale (GAIS)
Description
Subject- graded GAIS at 12-week post-final treatment follow-up.
Time Frame
Final post treatment 1 day visit

10. Eligibility

Sex
All
Minimum Age & Unit of Time
22 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria Male and female subjects > 22 years of age and ≤65 years of age. Subject has not had weight change exceeding 5% of body weight in the preceding month. Subject agrees to maintain her weight (i.e., within 5%) by not making any major changes in diet or exercise routine during the course of the study. Subject agrees to refrain from any new abdominal training exercises during the course of the study. BMI ≤ 30 kg/m2 as determined at screening. Abdominal skin fold thickness 2.0 to 5.0 cm, as measured by caliper below umbilicus. Subject has read and signed a written informed consent form. Exclusion Criteria Subject has had a surgical procedure(s) in the area of intended treatment. Subject has had an invasive fat reduction procedure (e.g., liposuction, mesotherapy) in the area of intended treatment. Subject has had a non-invasive fat reduction, body contouring and/or skin tightening procedure in the area of intended treatment within the past 12 months. Subject has numbness, tingling or other altered sensation in the treatment area. Subject needs to administer, or has a known history of subcutaneous injections into the area of intended treatment (e.g., heparin, insulin) within the past month. Subject has not had an intrauterine contraceptive device inserted or removed within the past month. Subject has a known history of cryoglobulinemia, cold urticaria, cold agglutinin disease, or paroxysmal cold hemoglobinuria Subject has a known history of Raynaud's disease, or any known condition with a response to cold exposure that limits blood flow to the skin. Subject has a history of bleeding disorder or is taking any medication that in the Investigator's opinion may increase the subject's risk of bruising. Subject has known sensitivity or allergy to isopropyl alcohol and propylene glycol, or latex. Subject is taking or has taken diet pills or supplements within the past month. Subject has any dermatological conditions, such as moderate to excessive skin laxity, or scars in the location of the treatment sites, that may interfere with the treatment or evaluation (stretch marks is not an exclusion). Subject has a metal implant or active implanted device such as a pacemaker, defibrillator, or drug delivery system. Subject has been involved in any type of abdominal muscle training program within the previous 6 months. Subject has pulmonary insufficiency. Subject has a cardiac disorder. Subject has a malignant tumor. Subject has been diagnosed with epilepsy. Subject currently has a fever. Subject is pregnant or intending to become pregnant during the study period (in the next 9 months). Subject is lactating or has been lactating in the past 6 months. Subject is unable or unwilling to comply with the study requirements. Subject is currently enrolled in a clinical study of any other investigational drug or device. Any other condition or laboratory value that would, in the professional opinion of the Investigator, potentially affect the subject's response or the integrity of the data or would pose an unacceptable risk to the subject.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Kerrie Jiang, NP
Organizational Affiliation
Zeltiq Aesthetics
Official's Role
Study Director
Facility Information:
Facility Name
Marina Plastic Surgery
City
Marina Del Rey
State/Province
California
ZIP/Postal Code
90292
Country
United States
Facility Name
Innovation Research Center
City
Pleasanton
State/Province
California
ZIP/Postal Code
94588
Country
United States
Facility Name
Laser & Skin Surgery Center of Northern California
City
Sacramento
State/Province
California
ZIP/Postal Code
95816
Country
United States
Facility Name
Aesthetic Solutions, P.A.
City
Chapel Hill
State/Province
North Carolina
ZIP/Postal Code
27517
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

CoolSculpting and EMS for the Abdomen

We'll reach out to this number within 24 hrs